1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,850 | 8,050 | 14:28 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | BIOCYTOGEN-B (02315): 2026 INTERIM REPORT | - | HKEx | ||
| 16.09. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 16, 2026 | - | HKEx | ||
| 03.09. | Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule | 3 | Pharmaceutical Technology | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 02.09. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience | 456 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd.... ► Artikel lesen | |
| 27.08. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Reports Climb In H1 Bottom Line | 1 | RTTNews | ||
| 27.08. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2026 THIRD EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, SEPTEMBER 16, 2026 | - | HKEx | ||
| 27.08. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.08. | BIOCYTOGEN-B (02315): CHANGE IN IMPLEMENTATION METHOD OF CERTAIN PROCEEDS-FUNDED PROJECT; AND NOTICE OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 27.08. | BIOCYTOGEN-B (02315): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 17.08. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | - | HKEx | ||
| 06.08. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT OF ESTIMATED INTERIM RESULTS FOR 2026 | 1 | HKEx | ||
| 08.07. | Biocytogen and Whitehawk partner to develop ADCs | 1 | Pharmaceutical Technology | ||
| 07.07. | Biocytogen und Whitehawk Therapeutics vereinbaren weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten (ADC) | 464 | Business Wire | Biocytogen (SSE: 688796; HKEX: 02315) und Whitehawk Therapeutics, Inc. ("Whitehawk", Nasdaq: WHWK) gaben heute eine weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten... ► Artikel lesen | |
| 07.07. | Whitehawk swoops in for five ADCs via development deal with China's Biocytogen | 3 | FierceBiotech | ||
| 07.07. | Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development | 514 | Business Wire | Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. ("Whitehawk," Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen... ► Artikel lesen | |
| 29.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Gericht gibt Biocytogen im wegweisenden Patentstreit gegen Harbour in Bezug auf RenNano Recht | 474 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) hat heute bekannt gegeben, dass das Gericht für geistiges Eigentum in Shanghai ein erstinstanzliches Zivilurteil... ► Artikel lesen | |
| 29.06. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT DEVELOPMENT OF LITIGATION | 2 | HKEx | ||
| 25.06. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JUNE 25, 2026 | 1 | HKEx | ||
| 16.06. | Biocytogen erhält die vollumfängliche AAALAC-Akkreditierung, was die Exzellenz in der translationalen Forschung und der Wirkstoffentdeckung unterstreicht | 373 | Business Wire | Biocytogen teilte heute mit, dass seine Forschungseinrichtung in Boston die Vollakkreditierung durch AAALAC International erhalten hat, eine weltweit renommierte Organisation, deren Ziel die Förderung... ► Artikel lesen | |
| 15.06. | Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery | 315 | Business Wire | Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,004 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| BIOFRONTERA | 3,360 | -3,72 % | PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Biofrontera... ► Artikel lesen | |
| CLINUVEL | 5,074 | -1,78 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,330 | +2,64 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| ASEP MEDICAL | 0,032 | -20,25 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,840 | 0,00 % | Cellectar plant Phase-3-Studie und Zulassungsantrag für WM-Therapie | ||
| CARDIFF ONCOLOGY | 1,056 | -1,22 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| CLEAN HARBORS | 275,00 | +0,59 % | You Can Do Better Than Waste Management. Buy Clean Harbors Instead. | ||
| MESOBLAST | 1,316 | +0,96 % | Eli Lilly und Novo Nordisk bekommen neue Konkurrenz - warum der 100-Milliarden-Dollar-Markt immer mehr Biotech-Unternehmen anzieht | ||
| SPERO THERAPEUTICS | 1,085 | +1,88 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update | Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved... ► Artikel lesen | |
| LIR LIFE SCIENCES | 0,135 | -8,16 % | Lir Life Sciences Corp.: LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline | VANCOUVER, WA / ACCESS Newswire / July 16, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,440 | +0,21 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,636 | +0,19 % | CSTONE PHARMA-B (02616): INTERIM REPORT 2026 | ||
| PALVELLA THERAPEUTICS | 121,00 | 0,00 % | Palvella receives third year of FDA grant funding for therapy | ||
| PURPLE BIOTECH | 1,500 | -1,32 % | Purple Biotech Ltd.: New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies | REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy... ► Artikel lesen |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,65 % bei einem Aktienkurs von 7,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.